Rosiglitazone-containing Diabetes Medicines: Drug Safety Communication - FDA Eliminates the Risk Evaluation and Mitigation Strategy (REMS)

The REMS is no longer necessary to ensure that the benefits of rosiglitazone medicines outweigh their risks.